JP2026047359A5 - - Google Patents
Info
- Publication number
- JP2026047359A5 JP2026047359A5 JP2025160144A JP2025160144A JP2026047359A5 JP 2026047359 A5 JP2026047359 A5 JP 2026047359A5 JP 2025160144 A JP2025160144 A JP 2025160144A JP 2025160144 A JP2025160144 A JP 2025160144A JP 2026047359 A5 JP2026047359 A5 JP 2026047359A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- lymphoma
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901290P | 2019-09-17 | 2019-09-17 | |
| US62/901,290 | 2019-09-17 | ||
| PCT/US2020/051324 WO2021055638A1 (en) | 2019-09-17 | 2020-09-17 | Radiolabeling of anti-cd45 immunoglobulin and methods of use thereof |
| JP2022517380A JP7826190B2 (ja) | 2019-09-17 | 2020-09-17 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517380A Division JP7826190B2 (ja) | 2019-09-17 | 2020-09-17 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026047359A JP2026047359A (ja) | 2026-03-13 |
| JP2026047359A5 true JP2026047359A5 (https=) | 2026-04-08 |
Family
ID=74883490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517380A Active JP7826190B2 (ja) | 2019-09-17 | 2020-09-17 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
| JP2025160144A Pending JP2026047359A (ja) | 2019-09-17 | 2025-09-26 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517380A Active JP7826190B2 (ja) | 2019-09-17 | 2020-09-17 | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12605472B2 (https=) |
| EP (1) | EP4031188A4 (https=) |
| JP (2) | JP7826190B2 (https=) |
| CN (1) | CN114728074A (https=) |
| AU (1) | AU2020350677A1 (https=) |
| CA (1) | CA3154732A1 (https=) |
| WO (1) | WO2021055638A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023137335A2 (en) * | 2022-01-11 | 2023-07-20 | Actinium Pharmaceuticals, Inc. | Methods for treating cd33-positive hematological malignancies |
| JP2025510189A (ja) | 2022-03-24 | 2025-04-14 | アクティニウム ファーマシューティカルズ インコーポレイテッド | ヒト化抗ｃｄ４５抗体 |
| WO2025064402A1 (en) * | 2023-09-22 | 2025-03-27 | St. Jude Children's Research Hospital, Inc. | Method for treating sickle cell disease by targeting senescent cells |
| CN119842630B (zh) * | 2024-12-31 | 2025-12-26 | 江苏为真生物医药技术股份有限公司 | 抗人cd45单克隆抗体杂交瘤细胞株及分泌抗体及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273738A (en) * | 1990-03-03 | 1993-12-28 | Fred Hutchinson Cancer Research Center | Radiation delivery to lymphoid and marrow tissues |
| EP3297684B1 (en) * | 2015-05-21 | 2020-12-23 | Actinium Pharmaceuticals, Inc. | Infusion administration of conjugated monoclonal antibodies |
| CN108026526B (zh) * | 2015-06-09 | 2023-05-12 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| AU2016274989A1 (en) | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| WO2017155937A1 (en) * | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
| WO2019084273A1 (en) * | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES |
| US20230132400A9 (en) | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| WO2019136422A1 (en) * | 2018-01-08 | 2019-07-11 | Actinum Pharmaceuticals, Inc. | Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy |
| CA3137908A1 (en) | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
-
2020
- 2020-09-17 US US17/761,579 patent/US12605472B2/en active Active
- 2020-09-17 EP EP20864847.7A patent/EP4031188A4/en active Pending
- 2020-09-17 WO PCT/US2020/051324 patent/WO2021055638A1/en not_active Ceased
- 2020-09-17 CN CN202080078786.2A patent/CN114728074A/zh active Pending
- 2020-09-17 CA CA3154732A patent/CA3154732A1/en active Pending
- 2020-09-17 JP JP2022517380A patent/JP7826190B2/ja active Active
- 2020-09-17 AU AU2020350677A patent/AU2020350677A1/en active Pending
-
2025
- 2025-09-26 JP JP2025160144A patent/JP2026047359A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026047359A5 (https=) | ||
| US12564651B2 (en) | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging | |
| EP1853313B1 (en) | Humanized l243 antibodies | |
| US7829064B2 (en) | Anti-CD74 immunoconjugates and methods | |
| CA2378584C (en) | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy | |
| Davies | Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab | |
| DK2914302T3 (en) | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT | |
| CN102174108B (zh) | 内在化抗-cd74抗体和使用方法 | |
| PL216208B1 (pl) | Zastosowanie kompozycji leczniczej zawierającej niesprzężone i sprzężone przeciwciała w immunoterapii nowotworów złośliwych i choroby autoimmunizacyjnej | |
| HU229627B1 (en) | Radiolabeling kit and binding assay | |
| CN104114192A (zh) | 嵌合的治疗性抗-cd37抗体hh1 | |
| BG65929B1 (bg) | Селективно антитяло за свързан с туморнекрозисния фактор лиганд рецептор, причиняващо апоптоза, и използването му | |
| CN112533952B (zh) | 治疗疾病或病况的组合物及其用途 | |
| JP2021522303A5 (https=) | ||
| JP2022548694A5 (https=) | ||
| JP2022548694A (ja) | 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 | |
| JP2020500161A5 (https=) | ||
| CA2283540A1 (en) | Anti-fas antibodies | |
| JP7704748B2 (ja) | 逐次抗ｃｄ１９治療 | |
| AU734758B2 (en) | Anti-fas antibodies | |
| WO2023056474A1 (en) | Mouse anti-human monoclonal antibody against glypican-3 | |
| Kawashima | Characteristics of Ibritumomab as radionuclide therapy agent | |
| KR20260022886A (ko) | 방사성동위원소 표지된 cd25 표적 항체를 유효성분으로 포함하는 암의 방사면역치료용 약제학적 조성물 | |
| Kawashima | as Radionuclide Therapy Agent | |
| WO2011144744A1 (en) | Targeted radioactive compound for human cd66 for the treatment of disorders |